EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal

Mehdi Haghdoost, Jennifer LaBranche, Matthew Roberts, Victor W Li, Jane J Kim, James S H Wong, Pouya Azar iD

Addiction Biology · 2026

DOI: 10.1111/adb.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction Biology, 2026. Verfasst von Mehdi Haghdoost und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aidos Innovation, Sheridan, Wyoming, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Buprenorphine, Narcotic Antagonists, Opioid-Related Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VGH and UBC Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Buprenorphine (BUP) offers a therapeutic approach for opioid use disorder (OUD) due to its unique pharmacodynamic properties, primarily as a partial agonist with high affinity for the mu‐opioid receptor (MOR). BUP's partial agonism and ceiling effect on respiratory depression enhance its safety profile. However, BUP can induce precipitated withdrawal when administered after a full agonist, leading to severe withdrawal symptoms. This Perspective builds on prior work that has linked BUP's high‐affinity partial agonism to precipitated withdrawal and low‐dose induction strategies. We focus on how BUP's capacity to promote MOR externalization, together with its activity at the nociceptin opioid peptide (NOP) receptor, can help explain why it precipitates withdrawal when administered in the presence of full agonists yet relieves withdrawal once spontaneous withdrawal has begun. Understanding these mechanisms is critical for optimizing BUP protocols in OUD treatment and informs the potential development of new biased MOR agonists (i.e., ligands that preferentially activate specific signalling pathways) for addiction therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidBuprenorphineNarcotic AntagonistsOpioid-Related DisordersReceptors, Opioid, muSubstance Withdrawal SyndromeAnimalsHumansDrug Partial AgonismNociceptin ReceptorOpiate Substitution TreatmentReceptors, Opioid

Stichwörter der Autor:innen

biased agonistsbuprenorphinemu‐opioid receptoropioid use disorderprecipitated withdrawal

Substanzen

Analgesics, OpioidBuprenorphineNarcotic AntagonistsNociceptin ReceptorReceptors, OpioidReceptors, Opioid, mu

Autor:innen und Institutionen

  • Aidos Innovation, Sheridan, Wyoming, USA.
  • Complex Pain and Addiction Service, Department of Psychiatry, Vancouver Coastal Health, Vancouver, Canada.
  • Department of Psychiatry, Faculty of Medicine, University of British Columbia, Vancouver, Canada.

ORCID-Profile: Pouya Azar

Förderung

  • VGH and UBC Hospital Foundation

Zitieren

APA

Haghdoost, M., LaBranche, J., Roberts, M., Li, V. W., Kim, J. J., Wong, J. S. H., & Azar, P. (2026). The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal. Addiction Biology. https://doi.org/10.1111/adb.70126

Vancouver

Haghdoost M, LaBranche J, Roberts M, Li VW, Kim JJ, Wong JSH, et al. The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal. Addiction Biology. 2026. doi:10.1111/adb.70126

BibTeX
@article{Haghdoost2026,
  author = {Haghdoost, Mehdi and LaBranche, Jennifer and Roberts, Matthew and Li, Victor W and Kim, Jane J and Wong, James S H and Azar, Pouya},
  title = {The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal},
  journal = {Addiction Biology},
  year = {2026},
  doi = {10.1111/adb.70126}
}
Kostenlos starten →